|
1
|
Moussavi S, Chatterji S, Verdes E, Tandon
A, Patel V and Ustun B: Depression, chronic diseases, and
decrements in health: Results from the World Health Surveys.
Lancet. 370:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nestler EJ, Barrot M, DiLeone RJ, Eisch
AJ, Gold SJ and Monteggia LM: Neurobiology of depression. Neuron.
34:13–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fava M: Diagnosis and definition of
treatment-resistant depression. Biol Psychiatry. 53:649–659. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trivedi MH, Rush AJ, Wisniewski SR,
Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz
B, McGrath PJ, et al: Evaluation of outcomes with citalopram for
depression using measurement-based care in STAR*D: Implications for
clinical practice. Am J Psychiatry. 163:28–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carvalho AF, Berk M, Hyphantis TN and
McIntyre RS: The integrative management of treatment-resistant
depression: A comprehensive review and perspectives. Psychother
Psychosom. 83:70–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conwell Y and Brent D: Suicide and aging.
I: Patterns of psychiatric diagnosis. Int Psychogeriatr. 7:149–164.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kochanek KD, Murphy SL, Anderson RN and
Scott C: Deaths: Final data for 2002. Natl Vital Stat Rep.
53:1–115. 2004.PubMed/NCBI
|
|
8
|
Weissman MM, Bland RC, Canino GJ,
Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine
JP, et al: Prevalence of suicide ideation and suicide attempts in
nine countries. Psychol Med. 29:9–17. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Petersen T, Gordon JA, Kant A, Fava M,
Rosenbaum JF and Nierenberg AA: Treatment resistant depression and
axis I co-morbidity. Psychol Med. 31:1223–1229. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lopresti AL, Maker GL, Hood SD and
Drummond PD: A review of peripheral biomarkers in major depression:
The potential of inflammatory and oxidative stress biomarkers. Prog
Neuropsychopharmacol Biol Psychiatry. 48:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miller AH and Raison CL: The role of
inflammation in depression: From evolutionary imperative to modern
treatment target. Nat Rev Immunol. 16:22–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rethorst CD, Bernstein I and Trivedi MH:
Inflammation, obesity, and metabolic syndrome in depression:
Analysis of the 2009–2010 National health and nutrition examination
survey (NHANES). J Clin Psychiatry. 75:e1428–e1432. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maes M, Bosmans E, De Jongh R, Kenis G,
Vandoolaeghe E and Neels H: Increased serum IL-6 and IL-1 receptor
antagonist concentrations in major depression and treatment
resistant depression. Cytokine. 9:853–858. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sluzewska A, Sobieska M and Rybakowski JK:
Changes in acute-phase proteins during lithium potentiation of
antidepressants in refractory depression. Neuropsychobiology.
35:123–127. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lanquillon S, Krieg JC, Bening-Abu-Shach U
and Vedder H: Cytokine production and treatment response in major
depressive disorder. Neuropsychopharmacology. 22:370–379. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mikova O, Yakimova R, Bosmans E, Kenis G
and Maes M: Increased serum tumor necrosis factor alpha
concentrations in major depression and multiple sclerosis. Eur
Neuropsychopharmacol. 11:203–208. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raison CL, Rutherford RE, Woolwine BJ,
Shuo C, Schettler P, Drake DF, Haroon E and Miller AH: A randomized
controlled trial of the tumor necrosis factor antagonist infliximab
for treatment-resistant depression: The role of baseline
inflammatory biomarkers. JAMA Psychiatry. 70:31–41. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weinberger JF, Raison CL, Rye DB, Montague
AR, Woolwine BJ, Felger JC, Haroon E and Miller AH: Inhibition of
tumor necrosis factor improves sleep continuity in patients with
treatment resistant depression and high inflammation. Brain Behav
Immun. 47:193–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sochor M, Basova P, Pesta M, Dusilkova N,
Bartos J, Burda P, Pospisil V and Stopka T: Oncogenic microRNAs:
miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early
breast cancer in serum. BMC Cancer. 14:4482014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garzon R and Croce CM: MicroRNAs in normal
and malignant hematopoiesis. Curr Opin Hematol. 15:352–358. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leng RX, Pan HF, Qin WZ, Chen GM and Ye
DQ: Role of microRNA-155 in autoimmunity. Cytokine Growth Factor
Rev. 22:141–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teng G and Papavasiliou FN: Shhh!
Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci.
364:631–637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Staszel T, Zapala B, Polus A,
Sadakierska-Chudy A, Kieć-Wilk B, Stepien E, Wybranska I, Chojnacka
M and Dembinska-Kiec A: Role of microRNAs in endothelial cell
pathophysiology. Pol Arch Med Wewn. 121:361–366. 2011.PubMed/NCBI
|
|
24
|
Zhu X, Wang Y, Sun Y, Zheng J and Zhu D:
MiR-155 up-regulation by LMP1 DNA contributes to increased
nasopharyngeal carcinoma cell proliferation and migration. Eur Arch
Otorhinolaryngol. 271:1939–1945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Wang W, Li X, He S, Yao J, Wang
X, Zhang D and Sun X: MicroRNA-155 promotes tumor growth of human
hepatocellular carcinoma by targeting ARID2. Int J Oncol.
48:2425–2434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang MM, Lin WJ, Pan YQ, Guan XT and Li
YC: Hippocampal neurogenesis dysfunction linked to depressive-like
behaviors in a neuroinflammation induced model of depression.
Physiol Behav. 161:166–173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stayte S, Rentsch P, Tröscher AR,
Bamberger M, Li KM and Vissel B: Activin a inhibits MPTP and
LPS-induced increases in inflammatory cell populations and loss of
dopamine neurons in the mouse midbrain in vivo. PLoS One.
12:e01672112017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng X, Huang H, Liu J, Li M, Liu M and
Luo T: Propofol attenuates inflammatory response in LPS-activated
microglia by regulating the miR-155/SOCS1 pathway. Inflammation.
41:11–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cardoso AL, Guedes JR, Pereira de Almeida
L and Pedroso de Lima MC: miR-155 modulates microglia-mediated
immune response by down-regulating SOCS-1 and promoting cytokine
and nitric oxide production. Immunology. 135:73–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wake H and Fields RD: Physiological
function of microglia. Neuron Glia Biol. 7:1–3. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Filipovic R and Zecevic N: Neuroprotective
role of minocycline in co-cultures of human fetal neurons and
microglia. Exp Neurol. 211:41–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanisch UK: Microglia as a source and
target of cytokines. Glia. 40:140–155. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smith JA, Das A, Ray SK and Banik NL: Role
of pro-inflammatory cytokines released from microglia in
neurodegenerative diseases. Brain Res Bull. 87:10–20. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kreutzberg GW: Microglia: A sensor for
pathological events in the CNS. Trends Neurosci. 19:312–318. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda
M, Sonobe Y, Takeuchi H and Suzumura A: Interleukin-34 selectively
enhances the neuroprotective effects of microglia to attenuate
oligomeric amyloid-β neurotoxicity. Am J Pathol. 179:2016–2027.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noda H, Takeuchi H, Mizuno T and Suzumura
A: Fingolimod phosphate promotes the neuroprotective effects of
microglia. J Neuroimmunol. 256:13–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Polazzi E and Monti B: Microglia and
neuroprotection: From in vitro studies to therapeutic applications.
Prog Neurobiol. 92:293–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yin H, Song S and Pan X: Knockdown of
miR-155 protects microglia against LPS-induced inflammatory injury
via targeting RACK1: A novel research for intracranial infection. J
Inflamm (Lond). 14:172017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoshimura A, Nishinakamura H, Matsumura Y
and Hanada T: Negative regulation of cytokine signaling and immune
responses by SOCS proteins. Arthritis Res Ther. 7:100–110. 2005.
View Article : Google Scholar : PubMed/NCBI
|
